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Abstract 
 
Background: Dengue is a kind of infectious disease that was distributed in the tropical and sub-tropical areas. To date, 
there is no clinically approved dengue vaccine or antiviral for humans, even though there have been great efforts 
towards this end. Therefore, finding the effective compound against dengue virus (DENV) replication is very 
important. Among the complex compounds, copper(II)-imidazole derivatives are of interest because of their biological 
and medicinal benefits.  
Materials and Methods: In the present study, antiviral activity of [Cu(2,4,5-triphenylimidazole)2]n, was evaluated 
against different stages of dengue virus type 2 (DENV-2) replication in Vero cell using focus forming unit reduction 
assay and quantitative ELISA.  
Results: [Cu(2,4,5-triphenylimidazole)2]n inhibited DENV-2 replication in Vero cells with IC50 = 2.3 μg/ml and SI= 
19.42 when cells were treated 2 days after virus infection, whereas its CC50 for cytotoxicity to Vero cells was 44.174 
μg/ml. 
Conclusion: The compound has high anti-DENV2 activity, less toxicity, and a high possibility to be considered a drug 
candidate.  
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Introduction 
 
Dengue is a kind of infectious disease that is distributed in the tropical and sub-tropical areas (Bhatt et al., 
2013; Franco et al., 2010; Guzman et al., 2010). Dengue is transmitted to human by Aedes aegypti. More than 250,000-
500,000 cases dengue infection occurred in the world every years (Bharaj et al., 2008; Reiter, 2001). Four distinct 
serotypes were reported, DENV-1, DENV-2, DENV-3, and DENV-4 (Balmaseda et al., 2006; Holmes and Twiddy, 
2003). Indonesia is one of the largest countries in the dengue-endemic region worldwide (Fahri et al., 2013; Kotaki et 
al., 2014; Kotaki et al., 2016; Setiati et al., 2006). In Indonesia, dengue occurred for the first time as an outbreak in 
Jakarta and Surabaya, in 1968 (Sumarmo, 1987). To date, there is no clinically approved dengue vaccine or antiviral for 
humans, even though there have been great efforts towards this end.  
2,3,5-triphenylimidazole, is a derivate of imidazole. The strong therapeutic properties of imidazole-containing 
drugs have encouraged medicinal chemists to synthesize a large number of novel chemotherapeutic agents comprising 
this entity. N5-(4-fluorophenyl)-N4-(2-(pyridin-4-yl)benzyl)-1H-imidazole-4,5-dicarboxamide, a derivate of imidazole, 
was reported anti-DENV activity (Saudi et al., 2014).   
The complex compound forms as a result of metal and organic compound reaction. It can be used as an anti-
inflammatory (Agotegaray et al., 2012), antimicrobial (Carcelli et al., 1995), antifungal, antibacterial (Arjmand et al., 
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2005), antivirus (Ranford et al., 1993). For example, Pt-acesulfame compound showeds a good inhibition of dengue 
virus replication mainly at 200 μM, when compared to the vehicle-treated cells (Cavicchioli et al., 2010). Therefore, in 
this research we sought to screen Cu(II)-Imidazole for dengue type 2 inhibition.     
 
Materials and Methods  
Materials 
 
Chemical reagents used in this research include copper(II)chloride dihydrate (CuCl2.2H2O) (Merck 99.0%), 
N,N-dimethyl formamide (DMF) (Merck 99.8%), 2,4,5-triphenylimidazole ligand (Sigma-Aldrich 90%), dimethyl 
sulfoxide (DMSO) (Sigma-Aldrich 99.8%)  and ethanol (Sigma-Aldrich 96%).  
Vero cells used for screening antiviral activity were incubated at 37 °C in Eagle’s minimum essential medium 
supplemented with 10% fetal bovine serum. Dengue virus type 2 (DENV-2) strains from Surabaya, Indonesia and cell 
monolayers were examined for the presence of viral antigen by immunostaining with a flavivirus-specific monoclonal 
antibody (D1-4G2; American Type Culture Collection, Manassas, VA).  
 
Methods  
Synthesis of [Cu(2,4,5-triphenylimidazole)2]n  
 
The compound was synthesized using solvothermal method with heating time of 3 hours at temperature of 
120°C (Han et al., 2012).   
 
Cytotoxicity assay 
 
Using WST-1 cell proliferation reagent (Roche Applied Science, Mannheim, Germany) (Chew et al., 2015). 
Vero cells (1 x 10
5
 cells/ml) were seeded in 96-well plate at 37 °C in 5% CO2 overnight. Following serial dilution 100 
µl of the compound was incubated with Vero cells for 24 h. 10 µl of Cell Proliferation Reagent WST-1 was added into 
each well, incubated for 1 hour at 37 °C. The plate was read at 450 nm (main filter) and 655 nm (reference filter) using 
an ELISA reader (iMark
TM
 Microplate Absorbance Reader).    
 
In vitro study 
 
Vero cells (1 x 10
5
 cells/ml) were also seeded in 96-well plate at 37 °C in 5% CO2 overnight. DENV-2 virus 
solution (MOI of 2) was prepared in MEM containing 10% FBS. Another serially diluted compound was added and 
incubated 37 °C for 1 hour. The supernatant was discarded and the pellet was washed with sterilized PBS three times, 
then MEM containing 10% FBS was added, followed by serially diluted test compound to the Vero cells incubated at 
37 °C for 2 days. The supernatant was used for ELISA at 450 nm (Wang et al., 2009) using an ELISA reader (iMark
TM
 
Microplate Absorbance Reader).   
 
Results and Discussions 
Cytotoxicity of [Cu(2,4,5-triphenylimidazole)2]n to DENV-2-infected Vero cells 
 
The result of the cell proliferation assay at 1 hour is shown in Figure 1. The compound, when added to Vero 
cells exhibited cytotoxic effects at CC50 = 44.74 µg/ml. One precent DMSO (negative control) did not show any 
cytotoxic effects against Vero cells.  
 
 
Figure 1: Linear curve for cytotoxicity of [Cu(2,4,5-triphenylimidazole)2]n 
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CC50 is cytotoxicity level of [Cu(2,4,5-triphenylimidazole)2]n (compound) to cause death to 50% of Vero cells. 
IC50 was calculated from regression linier curve; y = 1.0057x + 4.9992 with the axis (x) is concentration of compound 
and ordinate (y) is %viability.  
 
Inhibition of DENV-2 Infection by [Cu(2,4,5-triphenylimidazole)2]n in vitro 
 
The inhibitory ability of the compound against DENV-2 infection was determined via ELISA method. The 
compound was incubated with DENV-2 for 1 hour prior addition to Vero cells. The compound exhibited adsorption 
inhibitory activity against DENV-2 at IC50 = 2.3 µg/ml (SI value of 19.42). Percentage inhibition increased with 
increasing concentrations of compound (Figure 2). This indicates that dengue virus replication was inhibited. The 
inhibition at IC50 was not significantly high (p<0.005) compared to that of the metal-free imidazole (IC50 = 0.13 µg/ml). 
But, the metal-free imidazole more toxic for Vero cells (CC50 = 5.03 µg/ml) (Sucipto et al., 2017). However, studies on 
the compound of imidazole-4,5- showed higher antiviral potency against yellow fever virus (YFV) than dengue virus  
(DENV). This bioactivity may be within the imidazole series of a ‘para-‘attachment of a heterocycle to its ‘C’ (Saudi et 
al., 2014).       
 
 
 
Figure 2: Inhibition curve of [Cu(2,4,5-triphenylimidazole)2]n to DENV-2 
 
IC50 (maximal inhibitory concentration) is measure of the effectiveness of a substance in inhibiting a specific 
DENV-2. In this curve was used 8 concentration; 50 µg/ml, 25 µg/ml, 12.5 µg/ml, 6.25 µg/ml, 3.13 µg/ml, 1.56 µg/ml, 
0.78 µg/ml and 0.39 µg/ml. IC50 was calculated from regression linier curve; y = -5.1958x + 61.972. 
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